ELITE PHARMACEUTICALS INC /NV/ Quarterly Contract with Customer, Liability, Current in USD from Q1 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Contract with Customer, Liability, Current history and growth rate from Q1 2021 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Contract with Customer, Liability, Current for the quarter ending September 30, 2024 was $12.2K, a 8.33% decline year-over-year.
Contract with Customer, Liability, Current, Quarterly (USD)
Contract with Customer, Liability, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $12.2K -$1.11K -8.33% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $13.3K $0 0% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $13.3K $0 0% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 $13.3K $0 0% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $13.3K $0 0% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $13.3K $0 0% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $13.3K $0 0% Mar 31, 2023 10-K 2024-07-01
Q4 2022 $13.3K $0 0% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 $13.3K Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $13.3K Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $13.3K $0 0% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $13.3K Dec 31, 2021 10-Q 2022-02-14
Q1 2021 $13.3K Mar 31, 2021 10-K 2022-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.